Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients With Multiple Sclerosis

PLoS ONE - United States
doi 10.1371/journal.pone.0098588
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Public Library of Science (PLoS)

Related search

Biomarkers of Inflammation and Axonal Degeneration/Damage in Patients With Newly Diagnosed Multiple Sclerosis: Contributions of the Soluble CD163 CSF/Serum Ratio to a Biomarker Panel

PLoS ONE
Multidisciplinary
2015English

Interferon Inhibitory Activity in Patients With Multiple Sclerosis

Archives of Neurology
2006English

Role of Interlekin-35 as a Biomarker in Patients With Newly Diagnosed Hashimoto’s Thyroiditis

Endocrine Regulations
EndocrinologyMetabolismDiabetes
2016English

Induction Therapy and Stem Cell Mobilization in Patients With Newly Diagnosed Multiple Myeloma

Stem Cells International
Cell BiologyMolecular Biology
2012English

Time to Plateau as a Predictor of Survival in Newly Diagnosed Multiple Myeloma

American Journal of Hematology
Hematology
2018English

A Case Followed as Having Multiple Sclerosis but Diagnosed With Secondary Brain Lymphoma

Turk Noroloji Dergisi
Neurology
2015English

Prognostic Nomogram for the Overall Survival of Patients With Newly Diagnosed Multiple Myeloma

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2019English

Chromosome 1 Abnormalities in Elderly Patients With Newly Diagnosed Multiple Myeloma Treated With Novel Therapies

Haematologica
Hematology
2014English

Daratumumab in Untreated Newly Diagnosed Multiple Myeloma

Therapeutic Advances in Hematology
Hematology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy